Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

Short hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo

Authors: Hailan Yao, Yangde Zhang, Feng He, Caihong Wang, Zonghui Xiao, Jizhen Zou, Fang Wang, Zhewei Liu

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

Coxsackievirus B3 is an important infectious agent of viral myocarditis, pancreatitis and aseptic meningitis, but there are no specific antiviral therapeutic reagents in clinical use. RNA interference-based technology has been developed to prevent the viral infection.

Methods

To evaluate the impact of RNA interference on viral replication, cytopathogenicity and animal survival, short hairpin RNAs targeting the viral 2B region (shRNA-2B) expressed by a recombinant vector (pGCL-2B) or a recombinant lentivirus (Lenti-2B) were tansfected in HeLa cells or transduced in mice infected with CVB3.

Results

ShRNA-2B exhibited a significant effect on inhibition of viral production in HeLa cells. Furthermore, shRNA-2B improved mouse survival rate, reduced the viral tissues titers and attenuated tissue damage compared with those of the shRNA-NC treated control group. Lenti-2B displayed more effective role in inhibition of viral replication than pGCL-2B in vivo.

Conclusions

Coxsackievirus B3 2B is an effective target of gene silencing against coxsackievirus B3 infection, suggesting that shRNA-2B is a potential agent for further development into a treatment for enterviral diseases.
Appendix
Available only for authorised users
Literature
1.
Huber SA, Gauntt CJ, Sakkinen P: Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Adv Virus Res. 1998, 51: 35-80.CrossRefPubMed
2.
Esfandiarei M, McManus BM: Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol. 2008, 3: 127-155. 10.1146/annurev.pathmechdis.3.121806.151534.CrossRefPubMed
3.
Mena I, Fischer C, Gebhard JR, Perry CM, Harkins S, Whitton JL: Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology. Virology. 2000, 271: 276-288. 10.1006/viro.2000.0332.CrossRefPubMed
4.
Wong AH, Lau CS, Cheng PK, Ng AY, Lim WW: Coxsackievirus B3-associated aseptic meningitis: an emerging infection in Hong Kong. J Med Virol. 2011, 83 (3): 483-489. 10.1002/jmv.21998.CrossRefPubMed
5.
Grist NR, Reid D: Epidemiology of viral infections of the heart. Viral infections of the heart. Edited by: Banatvala JE. 1993, London: Edward Arnold, 23-30.
6.
Wimmer E, Hellen CU, Cao X: Genetics of poliovirus. Annu Rev Genet. 1993, 27: 353-436. 10.1146/annurev.ge.27.120193.002033.CrossRefPubMed
7.
Fairweather D, Rose NR: Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods. 2007, 41 (1): 118-122. 10.1016/j.ymeth.2006.07.009.CrossRefPubMedPubMedCentral
8.
Gauntt CJ, Tracy SM, Chapman N, Wood HJ, Kolbeck PC, Karaganis AG, Winfrey CL, Cunningham MW: Coxsackievirus-induced chronic myocarditis in murine models. Eur Heart J. 1995, 16 (Suppl O): 56-58.CrossRefPubMed
9.
Tan FL, Yin JQ: RNAi, a new therapeutic strategy against viral infection. Cell Res. 2004, 14 (6): 460-466. 10.1038/sj.cr.7290248.CrossRefPubMed
10.
Ketzinel-Gilad M, Shaul Y, Galun E: RNA interference for antiviral therapy. J Gene Med. 2006, 8 (8): 933-950. 10.1002/jgm.929.CrossRefPubMed
11.
Zhou J, Rossi JJ: Progress in RNAi-based antiviral therapeutics. Methods Mol Biol. 2011, 721: 67-75. 10.1007/978-1-61779-037-9_4.CrossRefPubMed
12.
Chen Y, Cheng G, Mahato RI: RNAi for treating hepatitis B viral infection. Pharm Res. 2008, 25 (1): 72-86. 10.1007/s11095-007-9504-0.CrossRefPubMed
13.
Ashfaq UA, Yousaf MZ, Aslam M, Ejaz R, Jahan S, Ullah O: siRNAs: potential therapeutic agents against hepatitis C virus. Virol J. 2011, 8: 276-282. 10.1186/1743-422X-8-276.CrossRefPubMedPubMedCentral
14.
DeVincenzo JP: RNA interference strategies as therapy for respiratory viral infections. Pediatr Infect Dis J. 2008, 27 (Suppl 10): 118-122.CrossRef
15.
Ahn J, Jun ES, Lee HS, Yoon SY, Kim D, Joo C, Kim YK, Lee H: A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J Virol. 2005, 79 (13): 8620-8624. 10.1128/JVI.79.13.8620-8624.2005.CrossRefPubMedPubMedCentral
16.
Han J, Xiao Z, Yao H, Ren H, Liu Z: Short interfering RNA-mediated inhibition of coxsakievirus B infection in vitro. Chin J Exp Clin Virol. 2007, 21 (2): 150-152. Chinese
17.
Yao H, Xiao Z, Ren H, Han J, Liu Z: Study on inhibition of coxsackievirus B3 infection in HeLa cell by short interfering RNA targeting 2B protein. Bing Du Xue Bao. 2007, 23 (4): 276-281. ChinesePubMed
18.
Lodge PA, Herzum M, Olszewski J, Huber SA: Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms. Am J Pathol. 1987, 128 (3): 455-463.PubMedPubMedCentral
19.
Zhang J, Chen L, Zhang BY, Han J, Xiao XL, Tian HY, Li BL, Gao C, Gao JM, Zhou XB, Ma GP, Liu Y, Xu CM, Dong XP: Comparison study on clinical and neuropathological characteristics of hamsters inoculated with scrapie strain 263 K in different challenging pathways. Biomed Environ Sci. 2004, 17 (1): 65-78.PubMed
20.
Yuan J, Cheung PK, Zhang H, Chau D, Yanagawa B, Cheung C, Luo H, Wang Y, Suarez A, McManus BM, Yang D: A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts. Lab Invest. 2004, 84 (6): 703-814. 10.1038/labinvest.3700083.CrossRefPubMed
21.
Baboonian C, Davies MJ, Booth JC: Coxsackie B virus and human heart disease. Curr Top Microbiol Immunol. 1997, 223: 31-52. 10.1007/978-3-642-60687-8_3.PubMed
22.
23.
Merl S, Michaelis C, Jaschke B, Vorpahl M, Seidl S, Wessely R: Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation. 2005, 111 (13): 1583-1592. 10.1161/01.CIR.0000160360.02040.AB.CrossRefPubMed
24.
Yuan J, Cheung PK, Zhang HM, Chau D, Yang D: Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfectsequence match in the central region of the viral positive strand. J Virol. 2005, 79 (4): 2151-2159. 10.1128/JVI.79.4.2151-2159.2005.CrossRefPubMedPubMedCentral
25.
Kim JY, Chung SK, Hwang HY, Kim H, Kim JH, Nam JH, Park SI: Expression of short hairpin RNAs against the coxsackievirus B3 exerts potential antiviral effects in Cos-7 cells and in mice. Virus Res. 2007, 125 (1): 9-13. 10.1016/j.virusres.2006.11.009.CrossRefPubMed
26.
Fechner H, Sipo I, Westermann D, Pinkert S, Wang X, Suckau L, Kurreck J, Zeichhardt H, Müller O, Vetter R, Erdmann V, Tschope C, Poller W: Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J Mol Med. 2008, 86 (9): 987-979. 10.1007/s00109-008-0363-x.CrossRefPubMed
27.
Kim YJ, Ahn J, Jeung SY: Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model. Virus Genes. 2008, 36 (1): 141-146. 10.1007/s11262-007-0192-y.CrossRefPubMed
28.
Campanella M, de Jong AS, Lanke KW, Melchers WJ, Willems PH, Pinton P, Rizzuto R, van Kuppeveld FJ: The coxsackievirus 2B protein suppresses apoptotic host cell responses by manipulating intracellular Ca2+ homeostasis. J Biol Chem. 2004, 279 (18): 18440-18450. 10.1074/jbc.M309494200.CrossRefPubMed
Metadata
Title
Short hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo
Authors
Hailan Yao
Yangde Zhang
Feng He
Caihong Wang
Zonghui Xiao
Jizhen Zou
Fang Wang
Zhewei Liu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-177

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue

Research article

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation

Research article

Early sexual behaviour and Chlamydia trachomatisinfection – a population based cross-sectional study on gender differences among adolescents in Norway

Research article

HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes

Research article

A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection

Research article

Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study

Research article

High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naïve perinatally-infected children and adolescents with HIV-1 subtype C infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits